Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Platelets regulate glioblastoma growth and immunity via sex-dependent PAR4 - Estrogen receptor beta signaling.

bioRxiv : the preprint server for biology·2026
Same author

Addressing Psychosocial Syndemic Conditions to Improve HIV Testing among Men Who have Sex with Men in Chandigarh, India: Results from a Quasi-Experimental Implementation Research Study.

Indian journal of public health·2026
Same author

A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma.

Neuro-oncology·2025
Same author

Assessment of molecular tools in pediatric, adolescent, and young adult meningioma highlights the need for lifespan precision in neuro-oncology.

Neuro-oncology·2025
Same author

Composite Radiological Score (CRS)-A novel imaging biomarker: Correlation with clinical outcomes in patients with COVID-19 pneumonia.

The Indian journal of tuberculosis·2025
Same author

Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study.

The Lancet. Oncology·2025

Related Experiment Video

Updated: Jul 16, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Dendritic cell-based active specific immunotherapy for malignant glioma.

Prahlad Parajuli1, Saroj Mathupala, Sandeep Mittal

  • 1Wayne State University and Karmanos Cancer Institute, Department of Neurosurgery, Hudson-Webber CRC #808, 4100 John R St, Detroit, MI-48201, USA. pparajuli@med.wayne.edu

Expert Opinion on Biological Therapy
|March 22, 2007
PubMed
Summary

Dendritic cell immunotherapy shows promise for malignant gliomas by targeting residual cancer cells. Future strategies focus on overcoming immune suppression for more effective treatment.

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Experiment Videos

Last Updated: Jul 16, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Area of Science:

  • Neuro-oncology
  • Immunology
  • Cancer Therapy

Background:

  • Malignant gliomas are challenging to treat due to invasive tumor cells.
  • Dendritic cell (DC)-based immunotherapy aims to induce cell-mediated immunity and memory responses against residual glioma cells.
  • Early clinical trials showed limited success, necessitating further research.

Purpose of the Study:

  • To review the evolution of DC-based immunotherapy strategies for malignant gliomas.
  • To discuss novel approaches for enhancing DC maturation and activation.
  • To explore how understanding tumor-induced immune suppression influences future glioma immunotherapy.

Main Methods:

  • Review of existing literature on dendritic cell immunotherapy for malignant gliomas.
  • Analysis of studies investigating novel adjuvants for DC maturation.
  • Examination of research on tumor immune evasion mechanisms, including regulatory T cells.

Main Results:

  • Initial DC immunotherapy trials for gliomas yielded limited clinical benefits.
  • Development of new strategies using novel adjuvants to improve DC maturation and activation.
  • Increased focus on understanding tumor-intrinsic immune suppression and regulatory T cell roles.

Conclusions:

  • DC-based immunotherapy remains a promising avenue for adjuvant treatment of malignant gliomas.
  • Overcoming tumor-induced immune suppression is critical for enhancing therapeutic efficacy.
  • Future immunotherapy for high-grade gliomas will likely integrate insights into tumor tolerance mechanisms.